Results 221 to 230 of about 19,792 (277)
Some of the next articles are maybe not open access.
Hypolipidemic agents alter hepatic mitochondrial respiration in vitro
Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology, 1995The direct effects of three different classes of structurally diverse hypolipidemic agents on respiration were studied in mitochondria isolated from donor Sprague-Dawley rats. Two classes of peroxisome proliferators (i.e. plasticizers and hypolipidemic hormones and drugs) and one class of peroxisome inhibitors (i.e.
D S, Chance, M K, McIntosh
openaire +2 more sources
FDA considerations regarding new hypolipidemic agents
Lipids, 1977AbstractFood and Drug Administration policy being considered for new marketed hypolipidemic agents includes: long‐term safety to be demonstrated in postmarketing studies; evidence of clinical effectiveness to be demonstrated within a specified time period. Effectiveness is to be judged by one or more of the following: reduction in xanthomata, reduction
openaire +2 more sources
[Aryloxy- and arylthioalkylamine hypolipidemic agents].
Il Farmaco; edizione scientifica, 1983Aryloxy and arylthioalkylamines related respectively to clofibrate and 2-(3,5-di-t-butyl-4-hydroxyphenylthio)hexanoic acid, a derivative of an active probucol metabolite, were prepared and pharmacologically screened as hypolipidemic substances. Some of them showed interesting antilipemic activity but also, unfortunately, high acute toxicity.
DURANTI E +5 more
openaire +2 more sources
[Pharmacology of hypolipidemic agents].
Revue medicale de Bruxelles, 1997This review article examines the mode of action, the efficacy and the side effects of the various types of hypolipidemic agents (fibrates, bile acid sequestrants, statins, nicotinic acid and acipimox) currently available in Belgium. It also summarizes the recent guidelines recommended by the Belgian Lipid Club in the management of hyperlipidemia for ...
F, Féry, E O, Balasse
openaire +1 more source
[Peroxisomes and hypolipidemic agents ].
La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1982Peroxisomes (microbodies) have been localized in the cytoplasm of various cells, mainly the hepatocytes and the renal tubular cells. Various enzymes were found in the granular matrix and sometimes in the nucleus; they were involved in the production and the degradation of hydrogen peroxide, in regulation of the energetic processes of the cell, and in ...
F, Heller, S, Pourbaix
openaire +1 more source
Biological Activity of the Hypolipidemic Agent, N2-n-Butylindazolone
Journal of Pharmaceutical Sciences, 1984Previously, a series of N-substituted indazolone derivatives proved to be effective hypolipidemic agents in rodents. The most effective agent, N2-n-butylindazolone, at 20 mg/kg/d was shown to suppress the levels of cytoplasm acetyl coenzyme A required for cholesterol and fatty acid synthesis as well as sn-glycerol-3-phosphate acyl transferase and ...
I H, Hall +3 more
openaire +2 more sources
Biological Evaluation of Chalcones and Analogues as Hypolipidemic Agents
Archiv der Pharmazie, 2006AbstractIn order to evaluate the anti‐hyperlipidemic effect of synthetic chalcones and some analogues, nineteen compounds with different substituents in both rings were synthesized and hypolipidemic activities were measured in vivo using Triton WR1339 acute and hypercaloric chronic assays.
Lorena, Santos +5 more
openaire +2 more sources
Micronized Fenofibrate: A New Fibric Acid Hypolipidemic Agent
Annals of Pharmacotherapy, 1999OBJECTIVE: To review the efficacy and safety of fenofibrate in the management of hyperlipidemias. DATA SOURCES: A MEDLINE search (1974–October 1998), Current Contents search, additional references from article bibliographies, and the package insert from the manufacturer were used to identify data for evaluation.
openaire +2 more sources
Comparative study of several hypolipidemic agents related to clofibrate
Atherosclerosis, 1974Abstract Clofibrate and 3 related drugs (13.437 SU, GP 45.699 and MK 185) have been tested in man with the same protocol and by the same medical team. Comparison of the results of these clinical trials shows that the 4 drugs have common effects with regard to lipidemia, but differ in their action on uricemia and tolerance to antivitamin K: All of ...
V, Beaumont +3 more
openaire +2 more sources
Synthesis and Biological Evaluation of Orally Active Hypolipidemic Agents
Journal of Medicinal Chemistry, 2011A series of novel fenofibric acid ester prodrugs 1c-1h were synthesized and evaluated with the aim of obtaining potent hypolipidemic agents. Prodrugs 1c and 1d exhibited potent hypochlolesterolemic activity, lowering the mice plasma triglyceride level up to 47% in Swiss albino mice after oral administration of 50 mg/kg/day for 8 days.
Babasaheb P, Bandgar +5 more
openaire +2 more sources